Co-Administration of iRGD with Sorafenib-Loaded Iron-Based Metal-Organic Framework as a Targeted Ferroptosis Agent for Liver Cancer Therapy

Xianchuang Liu,1 Xinyang Zhu,1 Xun Qi,1 Xianwei Meng,2 Ke Xu1 1Department of Radiology and Key Laboratory of Diagnostic Imaging and Interventional Radiology of Liaoning Province, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, People’s Republic of China; 2Lab...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Liu X, Zhu X, Qi X, Meng X, Xu K
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	iron-based metal-organic framework irgd sorafenib ferroptosis hcc nanoparticles Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/c5db6dd37dd54e4e87e2cf9a71f9eef7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c5db6dd37dd54e4e87e2cf9a71f9eef7
record_format	dspace
spelling	oai:doaj.org-article:c5db6dd37dd54e4e87e2cf9a71f9eef72021-12-02T14:18:39ZCo-Administration of iRGD with Sorafenib-Loaded Iron-Based Metal-Organic Framework as a Targeted Ferroptosis Agent for Liver Cancer Therapy1178-2013https://doaj.org/article/c5db6dd37dd54e4e87e2cf9a71f9eef72021-02-01T00:00:00Zhttps://www.dovepress.com/co-administration-of-irgd-with-sorafenib-loaded-iron-based-metal-organ-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Xianchuang Liu,1 Xinyang Zhu,1 Xun Qi,1 Xianwei Meng,2 Ke Xu1 1Department of Radiology and Key Laboratory of Diagnostic Imaging and Interventional Radiology of Liaoning Province, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, People’s Republic of China; 2Laboratory of Controllable Preparation and Application of Nanomaterials, Laboratory of Cryogenics, Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Beijing, People’s Republic of ChinaCorrespondence: Ke XuDepartment of Interventional Radiology, The First Affiliated Hospital of China Medical University, No. 155 Nanjing North Street, Heping District, Shenyang, 110000, Liaoning, People’s Republic of ChinaTel +86 24 8328 2999Fax +86 24 8328 2997Email kxu@cmu.edu.cnPurpose: Hepatocellular carcinoma (HCC) is one of the most common fatal cancers, with no curative therapy available. The concept of ferroptosis is attracting increasing attention in cancer research. Herein, we describe the use of a nanodevice as an effective strategy for inducing ferroptosis to manage HCC.Methods: To improve ferroptosis-induced treatment of HCC, we constructed sorafenib (sor)-loaded MIL-101(Fe) nanoparticles (NPs) [MIL-101(Fe)@sor] and evaluated the efficacy of ferroptosis-based HCC therapy after co-administration with the iRGD peptide both in vitro and in vivo.Results: The prepared MIL-101(Fe) NPs have several promising characteristics including drug-loading, controllable release, peroxidase activity, biocompatibility, and T2 magnetic resonance imaging ability. MIL-101(Fe)@sor NPs significantly induced ferroptosis in HepG2 cells, increased the levels of lipid peroxidation and malondialdehyde, and reduced those of glutathione and glutathione peroxidase 4 (GPX-4). The in vivo results showed that the MIL-101(Fe)@sor NPs significantly inhibited tumor progression and decreased GPX-4 expression levels, with negligible long-term toxicity. Meanwhile, co-administration of MIL-101(Fe)@sor NPs with iRGD significantly accelerated ferroptosis.Conclusion: Our findings suggest that MIL-101(Fe)@sor NPs co-administered with iRGD are a promising strategy for inducing HCC ferroptosis.Keywords: iron-based metal-organic framework, iRGD, sorafenib, ferroptosis, HCC, nanoparticlesLiu XZhu XQi XMeng XXu KDove Medical Pressarticleiron-based metal-organic frameworkirgdsorafenibferroptosishccnanoparticlesMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 16, Pp 1037-1050 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	iron-based metal-organic framework irgd sorafenib ferroptosis hcc nanoparticles Medicine (General) R5-920
spellingShingle	iron-based metal-organic framework irgd sorafenib ferroptosis hcc nanoparticles Medicine (General) R5-920 Liu X Zhu X Qi X Meng X Xu K Co-Administration of iRGD with Sorafenib-Loaded Iron-Based Metal-Organic Framework as a Targeted Ferroptosis Agent for Liver Cancer Therapy
description	Xianchuang Liu,1 Xinyang Zhu,1 Xun Qi,1 Xianwei Meng,2 Ke Xu1 1Department of Radiology and Key Laboratory of Diagnostic Imaging and Interventional Radiology of Liaoning Province, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, People’s Republic of China; 2Laboratory of Controllable Preparation and Application of Nanomaterials, Laboratory of Cryogenics, Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Beijing, People’s Republic of ChinaCorrespondence: Ke XuDepartment of Interventional Radiology, The First Affiliated Hospital of China Medical University, No. 155 Nanjing North Street, Heping District, Shenyang, 110000, Liaoning, People’s Republic of ChinaTel +86 24 8328 2999Fax +86 24 8328 2997Email kxu@cmu.edu.cnPurpose: Hepatocellular carcinoma (HCC) is one of the most common fatal cancers, with no curative therapy available. The concept of ferroptosis is attracting increasing attention in cancer research. Herein, we describe the use of a nanodevice as an effective strategy for inducing ferroptosis to manage HCC.Methods: To improve ferroptosis-induced treatment of HCC, we constructed sorafenib (sor)-loaded MIL-101(Fe) nanoparticles (NPs) [MIL-101(Fe)@sor] and evaluated the efficacy of ferroptosis-based HCC therapy after co-administration with the iRGD peptide both in vitro and in vivo.Results: The prepared MIL-101(Fe) NPs have several promising characteristics including drug-loading, controllable release, peroxidase activity, biocompatibility, and T2 magnetic resonance imaging ability. MIL-101(Fe)@sor NPs significantly induced ferroptosis in HepG2 cells, increased the levels of lipid peroxidation and malondialdehyde, and reduced those of glutathione and glutathione peroxidase 4 (GPX-4). The in vivo results showed that the MIL-101(Fe)@sor NPs significantly inhibited tumor progression and decreased GPX-4 expression levels, with negligible long-term toxicity. Meanwhile, co-administration of MIL-101(Fe)@sor NPs with iRGD significantly accelerated ferroptosis.Conclusion: Our findings suggest that MIL-101(Fe)@sor NPs co-administered with iRGD are a promising strategy for inducing HCC ferroptosis.Keywords: iron-based metal-organic framework, iRGD, sorafenib, ferroptosis, HCC, nanoparticles
format	article
author	Liu X Zhu X Qi X Meng X Xu K
author_facet	Liu X Zhu X Qi X Meng X Xu K
author_sort	Liu X
title	Co-Administration of iRGD with Sorafenib-Loaded Iron-Based Metal-Organic Framework as a Targeted Ferroptosis Agent for Liver Cancer Therapy
title_short	Co-Administration of iRGD with Sorafenib-Loaded Iron-Based Metal-Organic Framework as a Targeted Ferroptosis Agent for Liver Cancer Therapy
title_full	Co-Administration of iRGD with Sorafenib-Loaded Iron-Based Metal-Organic Framework as a Targeted Ferroptosis Agent for Liver Cancer Therapy
title_fullStr	Co-Administration of iRGD with Sorafenib-Loaded Iron-Based Metal-Organic Framework as a Targeted Ferroptosis Agent for Liver Cancer Therapy
title_full_unstemmed	Co-Administration of iRGD with Sorafenib-Loaded Iron-Based Metal-Organic Framework as a Targeted Ferroptosis Agent for Liver Cancer Therapy
title_sort	co-administration of irgd with sorafenib-loaded iron-based metal-organic framework as a targeted ferroptosis agent for liver cancer therapy
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/c5db6dd37dd54e4e87e2cf9a71f9eef7
work_keys_str_mv	AT liux coadministrationofirgdwithsorafenibloadedironbasedmetalorganicframeworkasatargetedferroptosisagentforlivercancertherapy AT zhux coadministrationofirgdwithsorafenibloadedironbasedmetalorganicframeworkasatargetedferroptosisagentforlivercancertherapy AT qix coadministrationofirgdwithsorafenibloadedironbasedmetalorganicframeworkasatargetedferroptosisagentforlivercancertherapy AT mengx coadministrationofirgdwithsorafenibloadedironbasedmetalorganicframeworkasatargetedferroptosisagentforlivercancertherapy AT xuk coadministrationofirgdwithsorafenibloadedironbasedmetalorganicframeworkasatargetedferroptosisagentforlivercancertherapy
_version_	1718391632678617088

Co-Administration of iRGD with Sorafenib-Loaded Iron-Based Metal-Organic Framework as a Targeted Ferroptosis Agent for Liver Cancer Therapy

Ejemplares similares